C19orf33

Across TCGA pan-cancer cohorts, C19orf33 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated C19orf33 data layer compared with 27 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher C19orf33 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated C19orf33 expression acts as an unfavorable survival marker.

BLCA, BRCA, and LIHC are the cancer types where C19orf33 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	III,IV	0.085	0.684	<.001	24	view →
BRCA	OS	Median	All	0.107	0.578	<.001	12	view →
LIHC	OS	Median	All	0.025	0.777	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

C19orf33–BLCA (OS)

Open the BLCA breakdown →